Fusion Antibodies - Contract win
RNS
Latest announcements
Announcement summary
Fusion Antibodies - Contract win
Fusion Antibodies has been engaged to support a new Cell Line Development project with a US-based biotech company, reinforcing our role in scalable, high-quality antibody production. In our latest episode, CEO Adrian Kinkaid explores the supply stage of antibody development and how Fusion’s expertise in cell line development supports efficient manufacturing and clinical progress.
Ask a question
Your question will be sent privately to Fusion Antibodies plc. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Fusion Antibodies plc a question about this announcement.